AZD5153

DRUG2 trials

Sponsors

AstraZeneca, Acerta Pharma BV

Conditions

Breast CancerDLBCLDiffuse Large B Cell LymphomaLymphomaMalignant Solid TumorsNHLNon-hodgkin's LymphomaOvarian Cancer

Phase 1

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

CompletedNCT03205176

AstraZenecaBreast Cancer, Lymphoma, Malignant Solid Tumors +3

Start: 2017-06-30End: 2021-04-08Updated: 2021-05-06

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

CompletedNCT03527147

Acerta Pharma BVDiffuse Large B Cell Lymphoma, DLBCL, NHL +1

Start: 2018-06-19End: 2021-03-31Updated: 2022-08-15

Related Papers

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Blood2022-11-155 citations

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood2021-11-052 citations

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Blood2019-11-136 citations

First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.

Journal of Clinical Oncology2019-05-2023 citations